Porcine transmissible gastroenteritis virus epitope vaccine as well as preparation method and application thereof
By developing the FliCS.T-TGEV-S fusion protein epitope vaccine that utilizes the dominant B cell antigen epitope of the TGEV S protein RBD region, combined with the autologous adjuvant effect, the problem of poor prevention and control of the existing TGEV vaccine was solved, and efficient and safe immune protection effect was achieved.
CN119823287AActive Publication Date: 2025-04-15YANGZHOU UNIV
2 Cites 4 Cited by
Patent Information
- Application Number
- CN202510073147.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-17
- Publication Date
- 2025-04-15
- Estimated Expiration
- 2045-01-17
AI Technical Summary
Technical Problem
The prevention and control effect of existing pig infectious gastroenteritis virus (TGEV) vaccine is not ideal, and there are problems such as poor immunity durability and high cost.
Method used
An epitope vaccine was developed to utilize the dominant B-cell antigen epitope in the TGEV S protein receptor binding domain (RBD) region to improve the immune effect and safety of the vaccine by constructing the FliCS.T-TGEV-S fusion protein and combining the autologous adjuvant effect.
Benefits of technology
It significantly improves the immune protection effect of the vaccine, can induce high levels of neutralizing antibodies and cellular immune responses, provides comprehensive immune protection, and simplifies production processes and reduces costs.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to the technical field of biology, in particular to a swine transmissible gastroenteritis virus epitope vaccine and a preparation method and application thereof, the amino acid sequence of FliCS.T-TGEV-S fusion protein is shown as SEQ ID NO.3, and the nucleotide sequence of the FliCS.T-TGEV-S fusion protein is shown as SEQ ID NO.4. The fusion protein FliCS.T-TGEV-S prepared by the invention is used as an epitope vaccine based on dominant antigen epitopes of TGEV, and combines advanced means such as immunodominant epitopes, a fusion protein technology and genetic engineering, so that the specificity and the protection effect of the vaccine are enhanced. The vaccine not only can induce high-level antibody response and effectively inhibit TGEV infection, but also has relatively high safety and stability. Compared with a traditional vaccine, the vaccine has remarkable advantages in the aspects of production cost, immune efficacy, protection durability and the like, and a feasible TGE prevention and control scheme is provided for the pig industry.
Need to check novelty before this filing date? Find Prior Art